Roche Inks Deal with RBM/Psynova to Develop Diagnostics for 'Differentiating' Schizophrenia Therapies

While RBM and Psynova wouldn't reveal for which drug or drugs they were developing a companion diagnostic, there is an investigational schizophrenia agent in Roche's pipeline, RG 1678, which improved negative symptoms of patients with the disease in a Phase II proof-of-concept study. Separately, RBM and Psynova have also released data on a panel of central nervous system biomarkers they plan to develop into a homebrew diagnostic test for schizophrenia.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.